• ACVC Callout
News
ICViewExpert PerspectivesMedical World NewsVideosWebinars
Conference
Infection Control TodaySupplements And Featured Publications
CME/CEJob BoardPartnersSponsoredWhitepapers
Print SubscriptioneNewsletter
Educator of the Year Nomination FormEducator of the Year Official RulesEducator of the Year
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • Expert Perspectives on Personal Protection Guidelines and Standardization Practices
  • Bug of the Month
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
    • News
    • Conference
Advertisement

New Evidence Supports Biological Link Between Zika Infection, Guillain-Barre Syndrome

October 6, 2016
Article

In a collaborative effort with scientists at six Colombian hospitals, Johns Hopkins Medicine researchers report what they believe to be the strongest biological evidence to date linking Zika virus infection and Guillain-Barré syndrome.

Epidemiology data have long suggested a close relationship between rising Zika virus infection rates and instances of Guillain-Barré. The new study’s results, published on Oct. 5 in The New England Journal of Medicine, support the correlation with immunologic and viral evidence of Zika infection in a substantial number of people with Guillain-Barré, the investigators say.

Guillain-Barré is a very rare but potentially paralyzing disorder of the nervous system that appears days to weeks after infection with viruses or bacteria. A so-called post-infectious immune condition, it occurs when a person’s own immune system attacks the myelin sheaths that protect the body’s nerve cells, often resulting in muscle weakness, pain, sensory deficiencies and, in very acute cases, paralysis.

Guillain-Barré, which affects an estimated one or two out of 100,000 people after infections, is diagnosed with electrodiagnostic neurological tests that measure the conductive speed and activity of nerve signals. Scientists do not know why it strikes some people and not others. “At the beginning of the Zika outbreak in South America, my colleagues in Colombia contacted me with concern about the increasing number of patients with neurological complications in their hospitals,” says Carlos A. Pardo, MD, associate professor of neurology and pathology at the Johns Hopkins University School of Medicine, who earned his medical degree in Colombia and is an expert in neuroimmune and infectious diseases, including Guillain-Barré.

For the new study, Pardo’s team designed strategies with colleagues in Colombia to evaluate patients with suspected neurological problems associated with Zika and provided tools for viral tests of blood, cerebrospinal fluid and urine samples from 68 people with symptoms of Guillain-Barré. Of the 68 patients initially evaluated in Colombia, virus and immunology studies were conducted using the body fluids from 42. After some evaluation, the researchers found urine to be the most reliable fluid to diagnose Zika infection in patients with Guillain-Barré.

Seventeen patients tested positive for Zika virus in their urine. Another 18 had no evidence of Zika virus in urine but showed the immunologic footprints of Zika infection through the presence of virus-specific antibodies in their blood or spinal fluid. Most of the patients were adults - 38 were males, and 30 were females of an average of 47 years old. Almost all patients displayed two or more clinical symptoms of Zika infection, which include fever, headache, rash and conjunctivitis.

The researchers say that almost one-half of the study participants complained of neurologic symptoms within four days of the onset of Zika symptoms - an unusually fast response, they say, than is found in people who develop Guillain-Barré symptoms after other viral infections, such as influenza and herpesviruses.

Tests also revealed that most of the 46 patients whose Guillain-Barré was confirmed by electrodiagnostic neurological tests had the acute inflammatory demyelinating polyneuropathy variant of the disorder. This type of Guillain-Barré attacks the myelin, a protective group of cells that insulates the surface of the nerve fibers, like the plastic coating on a copper wire.

Pardo says the study is believed to be the largest of its kind to document the role of Zika infection in increased rates of Guillain-Barré so far. But he cautions that although the study demonstrates a biological and viral association between Zika infection and Guillain-Barré, it does not reveal the biological mechanisms through which Zika might initiate an immune attack on the nerves.

The research team, he says, continues to collect clinical data and samples from the Colombian hospitals’ patients, but the work is constrained by the limited availability of resources, which is further strained by the severe and ongoing Zika outbreak in South America.

Colombian researchers involved in this study include Beatriz Parra, Andreas F. Zea-Vera and Lydia Osorio, Universidad del Valle in Cali; Jairo Lizarazo, Hospital Universitario Erasmo Meoz, Universidad de Pamplona in Cucuta; Jorge Jimenez and Reydmar Lopez-Gonzales, Universidad de Antioquia and NeuroClinica in Medellin; Guillermo Gonzalez-Manrique and Cindy Beltran, Universidad Surcolombiana, Hospital Universitario de Neiva; Jose Vargas, Karen H. Rizcala and Maria T. Morales, Clinica La Misericordia Internacional, Universidad Libre de Colombia in Barranquilla; Jorge Angarita, Clinica MediLaser in Neiva; Gonzalo Zuñiga, Universidad del Valle, Hospital de Universitario del Valle in Cali; Oscar Pacheco and Martha Ospina Martinez, Instituto Nacional de Salud in Bogota. Other researchers at Johns Hopkins included Anupama Kumar, David Cornblath, Laura S. Muñoz and Paula Barreras from the Johns Hopkins University School of Medicine.

This study was funded by the Bart McLean Fund for Neuroimmunology Research, Johns Hopkins Project Restore, VIREM, the Virology Laboratory Fund and the Department of Microbiology at the Universidad de Valle.

Source: Johns Hopkins Medicine

Related Videos
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
COVID-19 germs, fungi, bacteria objects. (Adobe Stock 584704860 by chawalit)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Related Content

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Related Content
Advertisement

In this photo illustration, National Foundation for Infectious Diseases logo is seen displayed on a smartphone    (Adobe Stock 346303670 By Игорь Головнёв)

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023
Article

Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.


COVID-19 germs, fungi, bacteria objects.   (Adobe Stock 584704860 by chawalit)

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023
Article

As COVID-19 restrictions eased up, other respiratory viruses began circulating alongside SARS-CoV-2. It's crucial to identify cases and understand the symptoms of these infections to track the evolution of the virus and what health care workers should look out for.


An infection preventionist taking off her mask. (Adobe Stock, unknown)

I’m Not Just an Infection Preventionist

September 26th 2023
Article

Infection preventionists (IP) can come from many different backgrounds. This is 1 opinion from 1 very successful IP who doesn't have an RN or a BSN and the bullying that sometimes occurs.


(Adobe Stock FILE #:  56169337 by thinglass)

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023
Article

Many infection preventionists (IPs) disagree on the minimum requirement to have the IP position. Let Infection Control Today know your opinion. Answer this poll, and send your thoughts to Senior Editor Tori Whitacre Martonicz at tmartonicz@mjhlifesciences.com.


Influenza, RSV, and COVID-19 (AdobeStock_249346161, AdobeStock_538653843,AdobeStock_471755796)

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023
Article

The interaction between the respiratory viruses SARS-CoV-2, influenza, and RSV, poses ongoing challenges. Personal protective measures, testing, and vaccination are critical components of our strategy to mitigate the impact of these viruses.


weekly rounds with infection control today

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Article

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending September 24, 2023.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News